Doxil

Rediff.com » News » Doxil

News for Doxil

Business

Strong US growth to boost pharm cos' fortune in FY14

Sun, Lupin and Dr Reddy’s to lead here, with domestic formulations expected to rebound after Sept quarter. After posting a strong 20-plus per cent growth in the March quarter, top Indian......

Sensex falls 91 pts to 1-mth low

Extending losses for the fourth straight day, the BSE benchmark Sensex on Tuesday fell by over 91 points to end at one-month low level of 19,659.82 due to selling in ITC, RIL and ICICI Bank amid......

Sun Pharma gets USFDA nod for anti-cancer injection

Sun Pharmaceutical Industries on Tuesday said it has received US health regulator's approval to market generic version of Doxil injection, used in treating ovarian cancer in the American market.......

Sunset for profitable drug window in US

Advantage Johnson & Johnson (J&J) could mean loss for Sun Pharma. The Mumbai-based drug maker might soon have to stop exporting its cancer drug, Lipodox, to the US, as J&J is preparing a comeback......

Videos for Doxil

See All

Web results for Doxil

Strong US growth to boost pharm cos' fortune in FY14

Sun, Lupin and Dr Reddy’s to lead here, with domestic formulations expected to rebound after Sept quarter. After posting a strong 20-plus per... ...

http://www.rediff.com/money/report/strong-us-growth-to-boost-pharm-cos-fortune-in-fy14/20130612.htm

Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer

Overall Survival and Delayed Disease Progression is the Greatest Unmet Need in Platinum-Resistant Advanced Ovarian Cancer, According to a New... ...

http://www.asianhhm.com/news/news_archives.asp?NewsID=47903&title=Emerging-Targeted-Therapies-Offer-Efficacy-Advantages-Over-Currently-Used-Chemotherapies-for-PlatinumResistant-Advanced-Ovarian-Cancer

Preclinical and Phase 1 Data of VTX-2337 Presented at 2013 ASCO Annual Meeting Shows Early Activity in Ovarian Cancer

Data Support Ongoing Phase 2 Study in Platinum Resistant Ovarian Cancer PR Newswire SEATTLE, June 3, 2013 /PRNewswire/ --VentiRx Pharmaceuticals,... ...

http://www.asianhhm.com/news/news_archives.asp?NewsID=47197&title=Preclinical-and-Phase-1-Data-of-VTX2337-Presented-at2013-ASCO-Annual-Meeting-Shows-Early-Activity-in-Ovarian-Cancer

Dragged by weak sales, high costs

Cipla's gross profit margin (standalone) improved in the March quarter but its operating margin declined 0.6 percentage points due to higher... ...

http://www.thehindubusinessline.com/money-wise/stock-insight/cipla-dragged-by-weak-sales-high-costs/article4772601.ece

CLSA sees over 20% upside in Sun Pharma

NEW DELHI: CLSA has maintained 'buy' rating on with a price target of Rs 1220 per share, the Asian focused broker said in a report. At 12:30 p.m.;... ...

http://economictimes.indiatimes.com/markets/stocks/stocks-in-news/clsa-sees-over-20-upside-in-sun-pharma-post-q4-results/articleshow/20327123.cms

See All

Rediff News

Doxil

News for Doxil

Strong US growth to boost pharm cos' fortune in FY14

Sensex falls 91 pts to 1-mth low

Sun Pharma gets USFDA nod for anti-cancer injection

Sunset for profitable drug window in US

Top Coverage News

Indian Premier League - IPL 2013

Coverage: The Match-Fixing Episode II - spot-fixing trial

Sachin Tendulkar : Cup of praise overfloweth - Reactions

Complete coverage of Mumbai blasts

Decoding India’s Corruption Wars - Ajit Balakrishnan's Blog